Pharmacist Brad White will review current research on low-dose naltrexone and CBD Oil and how a compounding pharmacy can be a resource for treating autoimmune conditions like fibromyalgia, IBS, Crohn’s disease, and chronic pain. Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana The purpose of this study is to determine if the subjective effects of marijuana will be decreased by low-doses ( 50
Low Dose Naltrexone and CBD Oil Products Webinars
The Medicine Center Pharmacy is hosting an informational seminar for patients currently taking Low-Dose Naltrexone (LDN) and CBD oil products, or who are interested in learning more about its uses in the treatment of autoimmune disease and chronic pain.
We will review the state of the current research on its effectiveness for various conditions. Both CBD oil products and LDN have prompted many questions at our pharmacy and we are happy to share experiences and feedback with you. We will provide accurate information regarding the potential benefits of LDN and CBD oil from the experiences of our own patients, as well as to provide a forum to connect with others dealing with the difficulties of autoimmune and chronic pain disorders.
This seminar will examine the specific chronic pain conditions for which LDN has been shown to be an effective, non-opioid, treatment option for patients experiencing moderate to severe pain, inclusive of Complex Regional Pain Syndrome (CRPS), Fibromyalgia, Neuropathies, back pain and autoimmune disease. In addition, LDN’s unique ability to control pain in opioid-dependent patients, and assist in the tapering and elimination of opioids, will be reviewed. A comprehensive review of current literature will be discussed, its mechanism of action, as well as the clinical experience gained from the treatment of thousands of LDN patients, to form the clinical indication specific dosing guidance and titration protocols which are essential to achieving therapeutic success for your patients.
Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana
The purpose of this study is to determine if the subjective effects of marijuana will be decreased by low-doses ( < 25 mg) of naltrexone and increased by high-doses (>50 mg) of naltrexone.
|Condition or disease||Intervention/treatment||Phase|
|Marijuana Use||Drug: Placebo + Inactive Marijuana (0% THC) Drug: Placebo + Active Marijuana (3.27% THC) Drug: Naltrexone 12 Mg+ Active Marijuana (3.27% THC) Drug: Naltrexone 25 Mg + Active Marijuana (3.27% THC) Drug: Naltrexone 50 Mg+ Active Marijuana (3.27% THC) Drug: Naltrexone 100 Mg+ Active Marijuana (3.27% THC) Drug: Naltrexone 12 Mg + Inactive Marijuana (0% THC) Drug: Naltrexone 25 Mg + Inactive Marijuana (0% THC) Drug: Naltrexone 50 Mg + Inactive Marijuana (0% THC) Drug: Naltrexone 100 Mg + Inactive Marijuana (0% THC)||Phase 2|
Laboratory animal studies demonstrate that endogenous cannabinoids and opioids are closely inter-related. We have completed a series of studies in marijuana smokers showing that a clinically-utilized dose of naltrexone (50 mg) enhanced the reinforcing and subjective effects of orally-administered tetrahydrocannabinol (THC), while a low naltrexone dose (12 mg) blunted the effects of THC. A better understanding of the effects of a range of naltrexone doses in combination with smoked marijuana has important implications for the following reasons: (1) Alcohol- and opioid-dependent patients receive high doses of naltrexone (50-150 mg), which may increase the abuse liability of marijuana, (2) Low-dose naltrexone blunts THC’s intoxicating effects, suggesting potential utility as a treatment medication for marijuana dependence. This study will determine if naltrexone (0, 12, 25, 50, 100 mg) administration 45 min prior to marijuana administration (0, 3.27% THC) alters marijuana’s subjective, cognitive or physiological effects. Marijuana smokers will spend approximately 5h/day for a total of 10 days in the outpatient laboratory. Participants will visit the outpatient laboratory 2-3 times per week, with a minimum 48-hr interval between sessions to allow for naltrexone clearance. These data will provide important information regarding the clinical use of naltrexone.